Edesa Biotech

 

Contact Information:

Website: www.edesabiotech.com
Phone: (805) 488-2800
Email: info@edesabiotech.com
 

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases. The company recently reported favorable results from a Phase 2b study of its drug candidate, EB01 (daniluromer), as a monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis. Daniluromer is a first-in-class, non-steroidal anti-inflammatory compound that inhibits secretory phospholipase 2 (sPLA2) pro-inflammatory enzymes.